What we learnt: Ozempic makes Chemist Warehouse profits even fatter

Weight loss drugs are powering fresh growth at the pharmacy giant, DroneShield is talking soccer, and Cettire’s auditors aren’t happy.

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

NEWARK, CA / ACCESS Newswire / February 25, 2026 / Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today reported financial results for the fourth quarter and full year ended ...

Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; ...

FDA Draft Guidance Puts CRISPR Therapeutics Rare Disease Outlook In Focus

The FDA has issued draft guidance that could speed up approval pathways for rare disease therapies using genome editing technologies. This framework is directly relevant to CRISPR Therapeutics, which ...